NCT04405778: A Phase 1 Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GPC3
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have tumor with GPC3-expression
Exclusions: Patients with untreated unstable central nervous system (CNS) tumors- see trial for details

Comments are closed.

Up ↑